Impact of breast cancer subtypes and patterns of metastasis on outcome

Breast Cancer Research and Treatment

Volumn 150, Issue 3, 2015, Pages 621-629

  Kast, Karin ^a,b   Link, Theresa ^a,b   Friedrich, Katrin ^a,b   Petzold, Andrea ^a,b   Niedostatek, Antje ^a   Schoffer, Olaf ^a   Werner, Carmen ^a   Klug, Stefanie J ^a   Werner, Andreas ^c   Gatzweiler, Axel ^c   Richter, Barbara ^c   Baretton, Gustavo ^a,b   Wimberger, Pauline ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Diakonissenkrankenhaus Dresden ^*  (Germany)

Author keywords

Breast cancer; Metastases; Recurrence pattern; Subtypes

Indexed keywords

TUMOR MARKER;

BREAST TUMOR; CLASSIFICATION; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; SURVIVAL;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84939979930     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3341-3     Document Type: Article

References (25)

1. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Crosignani P, Danzon A et al (2004) Breast carcinoma survival in Europe and the United States. Cancer 100(4):715–722
2. Thomssen C, Diel I, Gnant M, Goldmann-Posch U, Goschke C, Haidinger R, Janni W, Lin NU (2012) Follow-up after breast cancer diagnosis. Breast Care (Basel, Switzerland) 8(6):457–460
3. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R et al (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22(16):3302–3308
4. Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, Delvart V, Azoulay D, Bismuth H, Castaing D (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244(6):897–907 discussion 907-898
5. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5(1):55–61
6. Falkson G, Gelman R, Falkson CI, Glick J, Harris J (1991) Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 9(12):2153–2161
7. Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub J (1992) Survival after first recurrence of breast cancer. The Miami experience. Cancer 70(1):129–135
8. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I et al (2008) Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 19(12):2012–2019
9. Rudat V, El-Sweilmeen H, Brune-Erber I, Nour AA, Almasri N, Altuwaijri S, Fadel E (2014) Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis. BMC Cancer 14(1):289
10. Vona-Davis L, Rose DP, Gadiyaram V, Ducatman B, Hobbs G, Hazard H, Kurian S, Abraham J (2014) Breast cancer pathology, receptor status, and patterns of metastasis in a rural appalachian population. J Cancer Epidemiol 2014:170634
11. Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Collins J, Fey MF, Coates AS et al (2009) Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 117(2):319–324
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423
13. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 22(8):1736–1747
14. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35
15. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(19):2078–2099
16. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804
17. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ et al (2006) HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Nat Compr Cancer Netw 4(Suppl 3):S1–22 quiz S23-24
18. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
19. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68(9):3108–3114
20. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98
21. Ribelles N, Perez-Villa L, Jerez JM, Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E, Marquez A et al (2013) Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res 15(5):R98
22. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281
23. Fiteni F, Villanueva C, Bazan F, Perrin S, Chaigneau L, Dobi E, Montcuquet P, Cals L, Meneveau N, Nerich V et al (2013) Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions. Breast (Edinburgh, Scotland) 23:165–169
24. Santini D, Vincenzi B, Pantano F, Tonini G, Bertoldo F (2011) Targeting bone metastases starting from the preneoplastic niche: home sweet home. Breast Cancer Res 13(4):111
25. Ignatiadis M, Dawson SJ (2014) Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol: Off J Eur Soc Med Oncol/ESMO 25:2304–2313